Eli Lilly and Company: Coronary Artery Disease trials
The registry lists 10 Coronary Artery Disease studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 3Phase 2 5Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseRecruitingNCT07839936Phase 2
- A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery DiseaseRecruitingNCT06164730Phase 1
- Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery DiseaseCompletedNCT01107925Phase 1Results posted
- Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery DiseaseCompletedNCT01107912Phase 1Results posted
- Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)TerminatedNCT00910299Phase 2Results posted
- Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)CompletedNCT00642174Phase 2Results posted
- Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With StentingCompletedNCT00357968Phase 2Results posted
- Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac EventCompletedNCT00356135Phase 2Results posted
- A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary InterventionCompletedNCT00097591Phase 3Results posted
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingNCT06383390Phase 3